Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
作者信息
Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Dougados M, Emery P, Gibofsky A, Kavanaugh A F, Keystone E C, Klareskog L, Russell A S, van de Putte L B A, Weisman M H
机构信息
University of California, UCLA, Rheumatology, Division Los Angeles, USA.
出版信息
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii2-9. doi: 10.1136/ard.62.suppl_2.ii2.
Abstract
摘要
相似文献
1
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).关于治疗类风湿关节炎及其他免疫介导的炎性疾病的生物制剂的更新共识声明（2003年5月）
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii2-9. doi: 10.1136/ard.62.suppl_2.ii2.
2
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.《2006年关于治疗风湿性疾病生物制剂的最新共识声明》
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
3
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.《2008年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.
4
Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.对安全性和成本的担忧使得生物制剂在类风湿关节炎治疗中的应用受到限制。
JAMA. 2003 Jun 25;289(24):3229-30. doi: 10.1001/jama.289.24.3229.
5
Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era: observations from Brazil.
J Clin Rheumatol. 2005 Dec;11(6):344-6. doi: 10.1097/01.rhu.0000191152.52925.31.
6
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.《2007年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
7
Drugs for rheumatoid arthritis.治疗类风湿性关节炎的药物。
Treat Guidel Med Lett. 2012 May;10(117):37-44; quiz 2 p following 44.
8
Management of rheumatoid arthritis.类风湿关节炎的管理
Natl Med J India. 2004 May-Jun;17(3):143-51.
9
[Biopharmaceuticals in the treatment of rheumatoid arthritis].[生物制药在类风湿关节炎治疗中的应用]
Ugeskr Laeger. 2008 Jun 9;170(24):2108-10.
10
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.2004年关于生物制剂（特别是肿瘤坏死因子α（TNFα）阻断剂和白细胞介素-1受体拮抗剂（IL-1ra））治疗风湿性疾病的更新共识声明。
Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272.
引用本文的文献
1
The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.csDMARDs 联合治疗对类风湿关节炎患者一线 TNF 抑制剂药物持久性的有益影响：来自捷克 ATTRA 登记处的数据。
Rheumatol Int. 2022 May;42(5):803-814. doi: 10.1007/s00296-021-05072-2. Epub 2022 Mar 26.
2
Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data.戈利木单抗剂量递增对日本类风湿关节炎患者的影响：上市后监测数据的事后分析
Rheumatol Ther. 2020 Jun;7(2):311-325. doi: 10.1007/s40744-020-00198-4. Epub 2020 Feb 29.
3
Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results.英夫利昔单抗剂量调整可改善类风湿关节炎患者的临床和影像学结局：REVIVE研究结果
Biologics. 2018 Nov 27;12:171-182. doi: 10.2147/BTT.S187998. eCollection 2018.
4
Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?类风湿关节炎患者中，与依那西普相比，阿达木单抗的停药风险是否受甲氨蝶呤联合用药剂量的影响？
Patient Prefer Adherence. 2016 Feb 5;10:123-34. doi: 10.2147/PPA.S94396. eCollection 2016.
5
A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.促进类风湿关节炎相关间质性肺疾病临床和转化研究的路线图。
Chest. 2014 Mar 1;145(3):454-463. doi: 10.1378/chest.13-2408.
6
TNF-alpha antagonist therapy modify the tuberculin skin test response.TNF-α拮抗剂治疗可改变结核菌素皮肤试验反应。
Rheumatol Int. 2011 Sep;31(9):1147-51. doi: 10.1007/s00296-010-1424-3. Epub 2010 Mar 27.
7
Higher C-reactive protein and soluble tumor necrosis factor receptor levels are associated with poor physical function and disability: a cross-sectional analysis of a cohort of late middle-aged African Americans.高 C 反应蛋白和可溶性肿瘤坏死因子受体水平与身体功能不良和残疾有关：一项对晚期中年非裔美国人队列的横断面分析。
J Gerontol A Biol Sci Med Sci. 2010 Mar;65(3):274-81. doi: 10.1093/gerona/glp148. Epub 2009 Oct 7.
8
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.肿瘤坏死因子α药物治疗类风湿关节炎：疗效与安全性的系统评价和荟萃分析
BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52.
9
The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.类风湿关节炎患者对英夫利昔单抗的临床反应部分取决于滑膜中肿瘤坏死因子α的预处理表达情况。
Ann Rheum Dis. 2008 Aug;67(8):1139-44. doi: 10.1136/ard.2007.080440. Epub 2007 Nov 29.
10
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.基于证据的类风湿关节炎疾病进展和缓解指标——生物标志物综述
Rheumatol Int. 2007 Jul;27(9):793-806. doi: 10.1007/s00296-007-0357-y. Epub 2007 May 16.
本文引用的文献
1
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.国际强直性脊柱炎评估工作组关于抗肿瘤坏死因子药物在强直性脊柱炎患者中应用的共识声明。
Ann Rheum Dis. 2003 Sep;62(9):817-24. doi: 10.1136/ard.62.9.817.
2
Case reports of heart failure after therapy with a tumor necrosis factor antagonist.肿瘤坏死因子拮抗剂治疗后发生心力衰竭的病例报告。
Ann Intern Med. 2003 May 20;138(10):807-11. doi: 10.7326/0003-4819-138-10-200305200-00008.
3
Successful treatment of resistant giant cell arteritis with etanercept.用依那西普成功治疗难治性巨细胞动脉炎。
Ann Rheum Dis. 2003 Apr;62(4):373-4. doi: 10.1136/ard.62.4.373.
4
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.免疫原性对英夫利昔单抗治疗克罗恩病长期疗效的影响。
N Engl J Med. 2003 Feb 13;348(7):601-8. doi: 10.1056/NEJMoa020888.
5
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.单核细胞增生李斯特菌感染作为肿瘤坏死因子α中和剂治疗的并发症。
Arthritis Rheum. 2003 Feb;48(2):319-24. doi: 10.1002/art.10758.
6
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.依那西普治疗多关节型幼年类风湿关节炎患儿的长期疗效及安全性：一项正在进行的多中心、开放标签、延长治疗试验的中期结果
Arthritis Rheum. 2003 Jan;48(1):218-26. doi: 10.1002/art.10710.
7
[Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].[类风湿关节炎中依那西普转换为英夫利昔单抗——131例接受抗TNFα治疗的患者中有14例]
Presse Med. 2002 Nov 23;31(39 Pt 1):1836-9.
8
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.如何从“复兴”中恢复？“恢复（RECOVER）”“复兴（RENAISSANCE）”“更新（RENEWAL）”和“附加（ATTACH）”研究结果的意义。
Int J Cardiol. 2002 Dec;86(2-3):123-30. doi: 10.1016/s0167-5273(02)00470-9.
9
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.危及生命的组织胞浆菌病使肿瘤坏死因子α拮抗剂英夫利昔单抗和依那西普的免疫治疗复杂化。
Arthritis Rheum. 2002 Oct;46(10):2565-70. doi: 10.1002/art.10583.
10
Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents.在免疫抑制试验中或接受生物制剂治疗的类风湿关节炎患者中诊断和治疗结核病的初步指南。
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii62-3. doi: 10.1136/ard.61.suppl_2.ii62.
Zotero 插件